Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cytosorbents Corporation - Common Stock
(NQ:
CTSO
)
0.9883
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 4, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cytosorbents Corporation - Common Stock
< Previous
1
2
3
4
5
Next >
Expert Outlook: CytoSorbents Through The Eyes Of 7 Analysts
January 13, 2025
Via
Benzinga
CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering
January 13, 2025
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai
January 06, 2025
From
CytoSorbents
Via
GlobeNewswire
Health Care Equipment Supplier CytoSorbents Shares Dip Despite Projected Revenue Growth
January 03, 2025
CytoSorbents is progressing with U.S. FDA and Health Canada reviews for its DrugSorb-ATR device.
Via
Benzinga
Topics
Supply Chain
Exposures
Product Safety
Supply Chain
Analyst Scoreboard: 5 Ratings For CytoSorbents
October 22, 2024
Via
Benzinga
Expert Outlook: CytoSorbents Through The Eyes Of 5 Analysts
October 22, 2024
Via
Benzinga
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue
January 03, 2025
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Rights Offering Begins
December 23, 2024
To Participate, Eligible Stockholders Should Consult Their Broker or Financial Advisor in Advance of the Rights Offering Expiration on January 10, 2025
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
December 12, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Announces Rights Offering
December 09, 2024
Investors Must Hold or Buy CTSO Common Stock by Close of Nasdaq Trading on Friday, December 13, 2024 to Participate
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
November 11, 2024
From
CytoSorbents; Converge Biotech
Via
GlobeNewswire
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
November 07, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification
November 04, 2024
From
CytoSorbents
Via
GlobeNewswire
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
October 22, 2024
DrugSorb™-ATR is an FDA Breakthrough Device eligible for priority review with an FDA decision anticipated in 2025
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results
October 17, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
October 01, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
August 27, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 16, 2024
From
CytoSorbents
Via
GlobeNewswire
CTSO Stock Earnings: CytoSorbents Beats EPS, Beats Revenue for Q2 2024
August 13, 2024
CTSO stock results show that CytoSorbents beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
August 13, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
August 13, 2024
CytoSorbents CFO Kathleen P. Bloch Retires
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
August 07, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement
August 01, 2024
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
July 29, 2024
“Working to Save Lives Together” Theme Highlights Two Decades of Successful Collaboration with the International Medical and Research Communities to Help Patients Survive Life-Threatening Illnesses
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress
July 17, 2024
From
CytoSorbents
Via
GlobeNewswire
Why CytoSorbents (CTSO) Stock Is Trading Higher
July 02, 2024
CytoSorbents shares are trading higher by 20% during Tuesday's session. The company entered into a new $20 million credit facility with Avenue Capital Group.
Via
Benzinga
CytoSorbents Secures $20 Million Credit Facility
July 02, 2024
Credit facility provides timely non-dilutive capital to support ongoing global commercialization of CytoSorb® as well as regulatory submissions and potential commercialization plans for DrugSorb™-ATR...
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan
June 24, 2024
Brings a powerful blood purification technology used to treat critically ill and cardiac surgery patients in nearly a quarter million treatments across 75 countries to date to one of the most...
From
CytoSorbents
Via
GlobeNewswire
CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union
June 13, 2024
By enabling more rapid and easy treatment, PuriFi is expected to increase the demand and sales of CytoSorbents’ leading CytoSorb® blood purification cartridge for critically ill patients in the...
From
CytoSorbents
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.